List of Excipients in Branded Drug SYNAGIS

Synagis Excipient Strategy and Commercial Opportunities for Palivizumab

Last updated: August 31, 2026

Synagis is a palivizumab monoclonal antibody used to reduce serious respiratory syncytial virus disease in high-risk pediatric patients. Its commercial formulation uses a narrow excipient system: histidine for pH control, glycine for stabilization, and mannitol as a bulking and tonicity-adjusting agent. The formulation creates opportunities in pediatric biologics, lyophilization, ready-to-use presentations, contract manufacturing, and differentiated delivery systems. The largest barriers are clinical comparability, low-dose pediatric administration, cold-chain control, and the regulatory burden associated with changing a licensed biologic formulation.

What excipients are used in Synagis?

Synagis uses a simple, preservative-free excipient platform.

Component	Functional role	Commercial relevance
Histidine	Buffer and pH control	Common in antibody formulations; supports protein stability near mildly acidic pH
Glycine	Stabilizer and tonicity modifier	Used in protein formulations and freeze-dried biologics
Mannitol	Bulking agent and tonicity modifier	Supports cake structure during lyophilization and improves handling of the dried product
Water for injection	Reconstitution medium or injectable vehicle	Required for parenteral administration

The U.S. presentation is supplied as a sterile, preservative-free lyophilized powder for reconstitution in single-dose vials. The labeled strengths are 50 mg and 100 mg of palivizumab. The formulation is reconstituted before intramuscular administration and has a target pH near 6.0.[1]

The formulation does not rely on surfactants such as polysorbate 20 or polysorbate 80 in the U.S. lyophilized product. That distinction matters because surfactants can reduce air-liquid interfacial stress but can introduce oxidation, hydrolysis, peroxide, and particulate risks. A formulation that avoids surfactants may simplify raw-material qualification, although it places greater importance on the lyophilization cycle, vial handling, agitation control, and container-closure performance.

How does the Synagis formulation work?

The excipient system addresses the principal stability problems of a protein biologic.

Histidine provides buffering near the formulation pH. Palivizumab is a recombinant IgG1 monoclonal antibody, and control of pH limits aggregation, chemical degradation, and changes in charge variants during storage.

Glycine contributes to protein stabilization and may help control solution tonicity. It is widely used in antibody products because it has a relatively limited reactivity profile and is suitable for parenteral formulations.

Mannitol provides the solid matrix required for an acceptable lyophilized cake. It can improve the physical appearance of the dried product and support reconstitution. Mannitol can crystallize during freezing, so its concentration and interaction with the protein and other excipients must be controlled. The freeze-drying cycle, rather than the excipient list alone, determines whether the final cake has acceptable residual moisture, reconstitution time, and long-term stability.

The commercial strategy is therefore based on a formulation-process combination:

1. Maintain antibody conformational stability.
2. Limit aggregation and visible or subvisible particles.
3. Produce a robust lyophilized cake.
4. Reconstitute rapidly with minimal foaming.
5. Preserve potency through the labeled storage period.
6. Support low-volume intramuscular dosing in infants and young children.

What formulation patents protect Synagis?

The core commercial protection for Synagis has historically centered on palivizumab, its production, therapeutic use, and biologic product rights rather than a broad, standalone excipient monopoly.

Publicly available regulatory materials identify the marketed product and its composition, but they do not establish that histidine, glycine, or mannitol individually remain protected by an enforceable composition-of-matter patent. These excipients are long-established pharmaceutical ingredients with extensive prior art and broad use across biologics.

Potential intellectual-property coverage may instead arise from:

• Specific palivizumab formulations.
• Defined protein-to-excipient ratios.
• Lyophilization cycles and solid-state properties.
• Container-closure systems.
• Manufacturing processes.
• Stability specifications.
• Methods of preventing respiratory syncytial virus disease.
• Dosing regimens for defined pediatric populations.
• Proprietary analytical methods.

A competitor cannot assume that using the same excipients is legally risk-free. Freedom-to-operate analysis must review active claims covering the antibody, formulation ranges, manufacturing process, delivery system, and method of use in each jurisdiction. The excipient names alone are unlikely to define the full patent risk.

When does Synagis lose exclusivity?

Synagis no longer benefits from the new-biologic exclusivity period that initially protected its BLA. The relevant regulatory framework is the biologics pathway under the Public Health Service Act, not the conventional small-molecule ANDA pathway.

Regulatory issue	Synagis position
Active ingredient	Palivizumab
Product type	Recombinant monoclonal antibody
U.S. application	BLA 103770
FDA pathway	Biologic license application
Conventional Orange Book listing	Not the primary U.S. biologic patent-record mechanism
Biosimilar pathway	Section 351(k) of the Public Health Service Act
Pediatric use	High-risk infants and children at increased risk of serious RSV disease
Formulation	Lyophilized, preservative-free injectable product

FDA-approved biologics are recorded through the Purple Book framework. The Orange Book is principally associated with approved small-molecule drugs and does not provide the same central patent-listing function for biologics.[2,3]

The practical consequence is that market entry depends on biosimilar or interchangeable-biologic development, patent and regulatory exclusivity analysis, manufacturing capability, and commercial positioning. A follow-on product would need to establish high similarity to palivizumab and address any residual uncertainty relating to immunogenicity, analytical similarity, potency, and product quality.

Are there Paragraph IV challenges for Synagis?

A traditional Paragraph IV ANDA challenge is not the principal route for palivizumab because Synagis is a biologic rather than a conventional small-molecule drug.

A competitor developing a follow-on palivizumab product would generally evaluate the 351(k) biosimilar pathway. Patent disputes could still arise, but the procedural framework differs from Hatch-Waxman litigation. The relevant analysis includes:

• Patent disclosures and certifications associated with the biosimilar process.
• The statutory patent-exchange process.
• Patent claims covering palivizumab, manufacturing, formulation, and use.
• Injunctive relief and launch timing.
• Settlement terms and any permitted entry date.
• Commercial-scale comparability data.

The absence of a conventional Paragraph IV filing does not remove litigation risk. It changes the pathway and the timing analysis.

What is the Orange Book status of Synagis?

Synagis is not best analyzed through Orange Book patent listings. Palivizumab is licensed as a biologic under BLA 103770, and the Purple Book is the more relevant FDA reference for biologic products and biosimilar status.[2]

For commercial diligence, the regulatory record should be separated into four categories:

Record	Purpose
FDA Drugs@FDA	Product label, approval history, supplements, and regulatory milestones
Purple Book	Biologic reference-product and biosimilar information
USPTO records	Patent ownership, prosecution, maintenance, and assignment data
Court and settlement records	Litigation, claim construction, settlements, and launch restrictions

An Orange Book search alone can produce an incomplete assessment of Synagis market-entry risk.

What biosimilar risk exists for Synagis?

The principal long-term threat is a palivizumab biosimilar or other follow-on biologic with lower acquisition cost and improved supply economics.

Technical barriers

Palivizumab developers must control:

• Primary sequence and higher-order structure.
• Glycosylation and charge-variant profiles.
• Aggregation and fragmentation.
• Fc-mediated functions where relevant.
• RSV neutralization potency.
• Binding to the intended viral antigen.
• Host-cell protein and residual DNA levels.
• Subvisible and visible particles.
• Immunogenicity risk.
• Stability after reconstitution.

The simple Synagis excipient system may reduce formulation complexity. It does not eliminate development risk. A biosimilar sponsor still must demonstrate that any formulation differences do not affect quality, safety, potency, or clinical performance.

Commercial barriers

Synagis has a concentrated seasonal market. Product demand is linked to RSV epidemiology, clinical guidelines, payer policies, birth cohorts, and eligibility restrictions. A biosimilar may obtain a lower price but still face:

• Short seasonal selling windows.
• Pediatric hospital and specialty-pharmacy contracting.
• Cold-chain requirements.
• Low tolerance for dosing or reconstitution errors.
• Physician preference for an established reference product.
• Inventory risk if RSV activity changes.
• Limited opportunity to recover development costs outside RSV prophylaxis.

The commercial case is strongest for a sponsor that can combine lower manufacturing cost with a smaller vial, ready-to-use format, improved logistics, or a broader supply commitment.

What formulation patents could create commercial opportunities?

The most credible formulation opportunities are not basic claims to histidine, glycine, or mannitol. They are differentiated product configurations that solve a defined clinical or manufacturing problem.

Ready-to-use liquid palivizumab

A liquid formulation could eliminate reconstitution and reduce preparation time. Its value would depend on maintaining antibody stability without lyophilization. Development variables include:

• Long-term aggregation.
• Oxidation and deamidation.
• Silicone-oil interaction.
• Protein adsorption to the container.
• Freeze-thaw tolerance.
• Particulate formation.
• Higher shipping and storage burden.
• Need for a suitable syringe or vial presentation.

A liquid product may be commercially attractive in neonatal and outpatient settings, but it could require more aggressive cold-chain control than a lyophilized presentation.

Prefilled syringe

A prefilled syringe could reduce preparation steps and medication errors. It may also support more efficient administration in ambulatory care. Key barriers include dose-volume control, device compatibility, extractables and leachables, injection force, protein adsorption, and stability during transport.

For an infant product, the syringe must support accurate dosing at small volumes. A prefilled presentation could be differentiated through usability rather than a new active ingredient.

Smaller-volume or higher-concentration product

A higher-concentration product could reduce injection volume. The formulation would need to preserve palivizumab stability while controlling viscosity, osmolality, injection force, and local tolerability.

A smaller injection volume may have meaningful value in pediatric care, but concentration changes can trigger a substantial comparability program. A concentration-based patent would need carefully drafted claims covering the protein concentration, excipient ratios, stability profile, and intended administration method.

Alternative stabilizers

Potential substitutes for the existing excipients could include sucrose, trehalose, arginine, or surfactants. Each option creates a different technical profile:

Excipient strategy	Potential benefit	Main risk
Sucrose or trehalose	Strong glass-forming stabilizers	Cake structure and residual moisture control
Arginine	May reduce aggregation in some proteins	pH, osmolality, and injection tolerability
Polysorbate	Reduces interfacial stress	Oxidation, peroxide burden, and particles
Histidine replacement	Alternative buffering profile	New pH and degradation behavior
Mannitol replacement	Different lyophilized matrix	Reconstitution and cake-collapse risk

A change to a known excipient may be scientifically reasonable, but the product still requires formulation screening, forced degradation, stability studies, and regulatory comparability work.

How strong is the Synagis excipient patent estate?

The excipient estate is likely weaker than a narrowly claimed formulation-process estate.

Relative strength by claim type

Claim category	Expected strategic value
Histidine, glycine, or mannitol individually	Low, because of extensive prior art and widespread use
Broad antibody formulation claims	Moderate to low unless narrowly tied to palivizumab performance
Defined excipient ratios and concentration ranges	Moderate if supported by unexpected stability data
Lyophilization process claims	Moderate, especially with defined cycle parameters and product attributes
Ready-to-use delivery systems	Moderate to high if device and stability claims are well drafted
Manufacturing process claims	Potentially high if difficult to design around
Method-of-use claims	Dependent on remaining enforceable scope and market jurisdiction

The most durable commercial protection would combine formulation claims with device, process, and product-by-process claims. A single claim to a conventional buffer and bulking agent is unlikely to create a strong barrier.

What manufacturing and IP barriers affect commercial entry?

Manufacturing palivizumab requires a validated mammalian-cell culture process, purification train, viral safety controls, aseptic filling, and either lyophilization or validated liquid-product handling.

The major barriers include:

1. Cell-line and upstream-process consistency.
2. Protein A and polishing-resin performance.
3. Viral clearance validation.
4. Aggregation control during concentration and filtration.
5. Low-bioburden and aseptic processing.
6. Lyophilization capacity and cycle reproducibility.
7. Container-closure integrity.
8. Cold-chain distribution.
9. Seasonal inventory planning.
10. Pediatric dose accuracy.

The excipient strategy affects cost of goods. Histidine, glycine, and mannitol are generally inexpensive compared with the antibody drug substance, sterile fill-finish, quality testing, and cold-chain logistics. The largest savings opportunity is therefore likely to come from process yield, vial utilization, fill-finish efficiency, and reduced handling rather than from replacing commodity excipients.

Which companies could challenge the Synagis market?

The competitive field includes several company types:

Biosimilar developers

These companies can use the 351(k) pathway to pursue a palivizumab biosimilar. Their advantages may include lower cost of goods, existing antibody manufacturing platforms, and established hospital or specialty-pharmacy channels.

Contract manufacturers

CDMOs can commercialize value through:

• Lyophilized biologic fill-finish.
• Prefilled syringe assembly.
• Analytical similarity testing.
• Stability-indicating assay development.
• Container-closure validation.
• Seasonal inventory management.

Formulation and device companies

A device-oriented entrant could compete through a ready-to-use syringe, reduced injection volume, or simplified reconstitution kit. Such products may require a commercial partnership with a biologics sponsor.

Competing RSV antibodies

The competitive benchmark has changed with newer long-acting RSV preventive antibodies and evolving pediatric RSV prevention recommendations. Nirsevimab has a longer dosing interval and targets broader seasonal use than palivizumab in many settings, creating a major commercial pressure point.[4,5]

How does Synagis compare with newer RSV prevention products?

Attribute	Synagis	Nirsevimab
Active ingredient	Palivizumab	Nirsevimab
Product class	Monoclonal antibody	Long-acting monoclonal antibody
Typical use model	Repeated seasonal dosing for eligible high-risk children	Single seasonal dose for broad infant protection in recommended populations
Formulation opportunity	Lyophilized product, reconstitution, potential liquid or device innovation	Long-acting, ready-to-administer commercial positioning
Main commercial constraint	Repeated administration and restricted eligibility	Supply, access, pricing, and seasonal procurement
Competitive implication	Strongest in defined high-risk populations and established channels	Stronger broad-population prevention proposition

The commercial opportunity for a Synagis follow-on is therefore narrower than a simple generic substitution opportunity. A new entrant must compete against both the reference product and newer prophylaxis strategies.

What is the revenue exposure and commercial opportunity?

Synagis revenue exposure is concentrated in seasonal RSV prevention and high-risk pediatric care. The product’s commercial value depends on:

• Annual eligible patient volume.
• Number of required doses per season.
• Payer reimbursement.
• Hospital and specialty-pharmacy purchasing.
• RSV season intensity.
• Regional treatment guidelines.
• Competition from long-acting alternatives.
• Manufacturing and inventory costs.

An excipient-led product can improve economics through lower administration burden and better supply efficiency. The strongest opportunities are:

1. A stable liquid presentation that eliminates reconstitution.
2. A prefilled syringe with accurate pediatric dosing.
3. A lower-volume product with acceptable injection tolerability.
4. A biosimilar with lower acquisition cost.
5. A regional fill-finish or supply partnership.
6. A formulation platform reusable across other monoclonal antibodies.
7. A contract manufacturing package combining formulation, lyophilization, and analytical release.

The commercial case is weaker for an excipient substitution that produces no visible improvement in price, convenience, shelf life, or supply reliability.

What is the likely litigation and settlement exposure?

A follow-on palivizumab sponsor should expect potential disputes involving:

• Biosimilar patent disclosures.
• Manufacturing-process patents.
• Antibody sequence or cell-line claims.
• Formulation and stability claims.
• Device and container-closure claims.
• Pediatric method-of-use patents.
• Regulatory exclusivity and launch timing.
• Settlement restrictions.

Settlement agreements could provide an agreed launch date, license terms, geographic limits, or restrictions on specific presentations. Publicly available information should be reviewed through FDA records, USPTO assignments, federal court dockets, and company filings before any launch forecast is finalized.

Key Takeaways

• Synagis uses a compact excipient system centered on histidine, glycine, and mannitol.
• The marketed product is a preservative-free lyophilized palivizumab injection supplied in 50 mg and 100 mg vials.
• The excipients are established pharmaceutical ingredients and are unlikely, by themselves, to create a strong exclusionary patent position.
• The strongest IP opportunities involve defined formulation ranges, lyophilization processes, liquid stability, delivery devices, and manufacturing controls.
• Synagis is a biologic under BLA 103770 and should be analyzed through the Purple Book and biologics patent framework rather than a conventional Paragraph IV Orange Book strategy.
• The main commercial opportunity is a follow-on or improved presentation that reduces reconstitution, injection burden, cost, or supply complexity.
• Nirsevimab and broader RSV prevention programs create substantial competitive pressure on palivizumab-based products.
• Excipient cost savings alone are unlikely to change the market. Commercial value must come from product performance, administration, manufacturing efficiency, or access.

FAQs

Can Synagis be reformulated without changing the biologic license?

A material excipient, concentration, dosage-form, or container change would generally require regulatory review under the applicable post-approval supplement pathway. The required data depend on the nature and effect of the change.

Is mannitol essential to Synagis performance?

Mannitol is important to the lyophilized presentation because it supports cake structure and tonicity. It is not necessarily irreplaceable, but a substitute would require evidence that the new solid matrix preserves potency, reconstitution, and stability.

Could a palivizumab biosimilar use different excipients?

Yes. A biosimilar may use a different formulation if the product remains highly similar and the differences do not create clinically meaningful changes. The sponsor must establish quality, safety, and efficacy comparability through the applicable regulatory program.

Does a ready-to-use Synagis syringe have patent value?

It can. Patent value may arise from the combination of palivizumab concentration, stability profile, syringe materials, dose accuracy, container closure, and administration method. Generic device claims alone may be easier to design around.

Is Synagis still commercially viable after nirsevimab?

Yes, but its opportunity is more concentrated. Synagis can remain relevant in high-risk pediatric populations, supply-constrained markets, and settings where established reimbursement and clinical pathways support repeated seasonal dosing.

References

1. U.S. Food and Drug Administration. (2023). Synagis (palivizumab) prescribing information. https://www.accessdata.fda.gov
2. U.S. Food and Drug Administration. (n.d.). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov
3. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
4. U.S. Food and Drug Administration. (2023). Beyfortus (nirsevimab-alip) prescribing information. https://www.accessdata.fda.gov
5. Centers for Disease Control and Prevention. (2023). RSV immunization guidance for infants and young children. https://www.cdc.gov/rsv/、】【